<DOC>
	<DOCNO>NCT03065556</DOCNO>
	<brief_summary>This Phase 2 study ( Study 203 ) design determine compare efficacy safety 188-0551 Solution Vehicle Solution apply twice daily four week subject plaque psoriasis . Subjects instruct apply test article ( 188-0551 Solution Vehicle Solution ) psoriasis plaque within designate Treatment Area twice daily four week ( Study Day 29 ) , unless investigator verifies subject 's psoriasis clear Day 15 , test article application 2 week ( Study Day 15 ) .</brief_summary>
	<brief_title>A Comparison 188-0551 Solution Versus Vehicle Solution Subjects With Plaque Psoriasis ( Study 203 )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Subject male nonpregnant female least 18 year age . 2 . Subject provide write informed consent . 3 . Subject willing able apply test article ( ) direct . 4 . Subject clinical diagnosis stable plaque psoriasis . 5 . Subject Investigator 's Global Assessment ( IGA ) score least three ( 3 = moderate ) Baseline Visit . 6 . Females must postmenopausal , surgically sterile use effective method birth control , negative urine pregnancy test ( UPT ) Baseline Visit . 1 . Subject spontaneously improve rapidly deteriorate plaque psoriasis . 2 . Subject guttate , pustular , erythrodermic nonplaque form psoriasis . 3 . Subject physical condition , investigator 's opinion , might impair evaluation plaque psoriasis . 4 . Subject use phototherapy ( include laser ) , photochemotherapy form photo base therapy treatment psoriasis within 30 day prior Baseline Visit . 5 . Subject use systemic tofacitinib , apremilast , methotrexate , retinoids , systemic corticosteroid [ include intralesional , intraarticular , intramuscular corticosteroid ] , cyclosporine analogous product within 90 day prior Baseline Visit . 6 . Subject use systemic antiinflammatory biologic therapy . 7 . Subject prolonged exposure natural artificial source ultraviolet radiation within 30 day prior Baseline Visit intending exposure study opinion investigator think modify subject 's disease . 8 . Subject use topical body ( exclude scalp ) psoriasis therapy ( include coal tar , anthralin , steroid , retinoids vitamin D analog ) within 14 day prior Baseline Visit . 9 . Subject use emollients/moisturizers area treat within four hour prior clinical evaluation Baseline Visit . 10 . Subject currently use lithium Plaquenil ( hydroxychloroquine ) . 11 . Subject currently use betablocking medication ( e.g. , propranolol ) angiotensin convert enzyme ( ACE ) inhibitor dose stabilize , opinion investigator . 12 . Subject history sensitivity corticosteroid ingredient test article . 13 . Subject pregnant , lactating , plan become pregnant study . 14 . Subject currently enrol investigational drug device study . 15 . Subject use investigational drug investigational device treatment within 30 day prior Baseline Visit . 16 . Subject previously enrol study treat test article .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>